Skip to search formSkip to main contentSkip to account menu

KW-2450

Known as: IGF-1R/IR Inhibitor KW-2450 
An orally bioavailable inhibitor of insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinases with potential… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background: KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We… 
2016
2016
Numerous solid tumors overexpress or have excessively activated insulin‐like growth factor receptor‐1 (IGF‐1R). We summarize… 
2015
2015
Currently, no targeted drug is available for triple-negative breast cancer (TNBC), an aggressive breast cancer that does not… 
2015
2015
Currently, no targeted drug is available for triple-negative breast cancer (TNBC), an aggressive breast cancer that does not… 
2013
2013
[Background] Both the insulin-like growth factor-1 receptor (IGF-1R) and insulin receptors (IR) have been found to be promising… 
2013
2013
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background/Hypothesis: Insulin growth factor-1… 
2013
2013
Recent studies found that TNBC had a highly activated profile in the insulin-like growth factor 1 receptor (IGF-1R)/insulin… 
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL KW-2450 is an orally active, multi-kinase inhibitor… 
2011
2011
3078 Background: KW-2450, a potent small molecule insulin-like growth factor receptor (IGF-1R)/insulin receptor (IR) antagonist…